🟢 Strong Evidence
Long-term follow-up data from the NI006-101 trial extension, published in Nature Medicine in June 2026, demonstrate that cliramitug, a monoclonal antibody targeting misfolded transthyretin, maintains safety and efficacy in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) over nearly two and a half years. The study extends evidence for this disease-modifying approach in a condition historically characterised by progressive cardiac deterioration and limited treatment options.
Key takeaways
- Median follow-up of 29.3 months showed continued reduction in cardiac amyloid burden without safety signals
- Structural, functional, and biomarker improvements persisted throughout the extended observation period
- Results suggest cliramitug may represent a paradigm shift from supportive care to amyloid-directed therapy in cardiac ATTR
Study at a Glance
| Source | Nature Medicine |
| Study type | Open-label extension cohort (long-term follow-up) |
| Follow-up duration | Median 29.3 months |
| Population | Patients with transthyretin amyloidosis cardiomyopathy |
| Intervention | Cliramitug (anti-misfolded transthyretin monoclonal antibody) |
| Country | Multicentre (international trial) |
Cardiac amyloid reduction and clinical outcome domains in cliramitug trials
Multi-domain response across amyloid burden, cardiac structure, function, and biomarkers; Nature Medicine NI006-101 extension, 2026
Data representation based on Nature Medicine (NI006-101 extension), June 2026 | Georgian Medical Journal News
A new therapeutic target in inherited cardiac disease
Transthyretin amyloidosis cardiomyopathy represents a rare but severe form of inherited cardiac disease, caused by deposition of misfolded transthyretin protein in the myocardium, leading to restrictive cardiomyopathy, arrhythmias, and progressive heart failure. Until recently, treatment remained largely supportive, focusing on symptom management and heart failure optimisation. The Nature Medicine report on cliramitug marks a fundamental shift toward disease-directed therapy by directly targeting misfolded transthyretin aggregates.
The mechanism of action sets cliramitug apart from earlier stabiliser-based approaches: rather than attempting to stabilise native transthyretin, cliramitug binds to misfolded transthyretin conformers and facilitates their clearance. This pathophysiological insight translates into clinical benefit observable across multiple cardiac domains—amyloid burden itself, myocardial structure measured by imaging, contractile and diastolic function, and circulating biomarkers of myocardial injury and stress.
Long-term safety and efficacy endpoints from the extension cohort
The NI006-101 extension study, with a median follow-up of 29.3 months reported in Nature Medicine, provides the longest safety and efficacy data currently available for anti-misfolded transthyretin monoclonal antibodies in ATTR-CM. The sustained reduction in cardiac amyloid burden—observed on repeat cardiac imaging—indicates that the therapeutic target remains engaged and that continued amyloid clearance occurs over the extended observation period. This contrasts sharply with the natural history of untreated ATTR-CM, in which progressive amyloid deposition drives inexorable functional decline.
Beyond amyloid quantification, the extension study documented improvements in left ventricular ejection fraction (LVEF) and strain parameters, signifying recovery of contractile function. Biomarkers of myocardial injury—cardiac troponin I (cTnI)—and neurohormonal stress—N-terminal pro-B-type natriuretic peptide (NT-proBNP)—showed favourable trends, aligning with the structural and functional gains observed on imaging. No new safety signals emerged during the extended follow-up, with adverse events consistent with the underlying disease and comorbidities rather than the investigational drug itself.
Clinical implications for cardiology and genetic disease management
The implications for clinical practice are substantial. ATTR-CM traditionally carried a poor prognosis, with median survival of 3–4 years from diagnosis in advanced stages. The demonstration of sustained amyloid reduction and functional improvement over nearly 30 months raises the possibility that early intervention with cliramitug could alter the natural history of the disease. This finding is particularly significant for patients with wild-type ATTR-CM (the most common form in elderly populations) and hereditary ATTR-CM, both of which currently have limited disease-modifying options beyond transthyretin stabilisers like tafamidis.
For clinicians managing ATTR-CM, the Nature Medicine data suggest that a direct anti-amyloid strategy may complement or, in some cases, supersede stabilisation therapy. The specific patient populations most likely to benefit—those with early-stage disease, high amyloid burden, or rapid functional decline—remain to be fully delineated in upcoming phase 3 trials. Additionally, the integration of cliramitug with standard heart failure therapies (ACE inhibitors, beta-blockers, aldosterone antagonists) requires further investigation to optimise combination strategies and prevent drug interactions.
Long-term follow-up for a median of 29.3 months in the NI006-101 extension demonstrated sustained reduction in cardiac amyloid burden and improvements across structural, functional, and biomarker endpoints, with a favourable safety profile.
— Nature Medicine, June 2026
Future directions and unmet needs in ATTR-CM therapeutics
While the NI006-101 extension results are encouraging, several questions remain. The optimal timing of cliramitug initiation relative to disease stage, the durability of benefit beyond 29 months, and whether amyloid reduction translates into symptom relief and improved quality of life in randomised controlled trials all require clarification. Additionally, the applicability of these findings to secondary amyloidosis (associated with systemic inflammation or chronic conditions) and other transthyretin variants remains unclear.
The ongoing development of anti-amyloid monoclonal antibodies has opened a new frontier in rare genetic disease management. The success of cliramitug in ATTR-CM may accelerate research into similar approaches for other amyloid-driven pathologies, including light-chain amyloidosis and other protein misfolding diseases. Policymakers and health technology assessment bodies will face decisions regarding access, cost-effectiveness, and appropriate patient selection as these therapies transition from clinical trials to real-world practice.
What this means
Frequently asked questions
What is transthyretin amyloidosis cardiomyopathy, and why is it difficult to treat?
ATTR-CM occurs when misfolded transthyretin protein accumulates in the heart muscle, causing progressive stiffness and impaired function. Traditional treatments stabilise remaining native protein but do not remove amyloid already deposited. Cliramitug is novel because it actively clears misfolded transthyretin, directly reducing amyloid burden—a mechanism not previously available in clinical practice.
How long does treatment with cliramitug need to continue?
The NI006-101 extension study shows sustained benefit over 29.3 months, but longer-term data on treatment duration, discontinuation strategies, and whether remission is possible are not yet available. Current evidence suggests ongoing therapy is required to maintain amyloid suppression, similar to other disease-modifying therapies in chronic conditions.
Will cliramitug be available to all ATTR-CM patients, or only a select group?
Regulatory approval and health system coverage will determine access. Likely early patient populations include those with symptomatic disease and elevated biomarkers or imaging evidence of active amyloid burden. Cost, manufacturing capacity, and health-economic evaluation will shape global availability and equitable access in different healthcare systems.
The NI006-101 extension data published in Nature Medicine represent a watershed moment for ATTR-CM management, confirming that direct anti-amyloid therapy can yield sustained clinical benefit over years-long follow-up. As these results move toward regulatory pathways and real-world implementation, the focus must shift to optimising patient selection, understanding long-term durability, and ensuring equitable access across diverse healthcare systems. The success of cliramitug validates the disease-directed therapeutic paradigm in rare genetic cardiomyopathies and sets a precedent for future anti-amyloid strategies.
Source: Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial, Nature Medicine, June 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
